Literature DB >> 11451706

Activities of gemifloxacin and five other antimicrobial agents against Listeria monocytogenes and coryneform bacteria isolated from clinical samples.

L Martínez-Martínez1, P Joyanes, A I Suárez, E J Perea.   

Abstract

The in vitro activities of gemifloxacin, ciprofloxacin, ampicillin, doxycycline, gentamicin, and vancomycin were evaluated against 15 Listeria monocytogenes strains and 205 coryneform bacteria isolated from clinical samples. The percentages of strains inhibited by gemifloxacin at 0.5 microg/ml were 100% (L. monocytogenes), 93.3% (Brevibacterium spp.), 90% (Corynebacterium minutissimum), 42.5% (Corynebacterium amycolatum), 20% (Corynebacterium striatum), 12.5% (Corynebacterium jeikeium), and 10% (Corynebacterium urealyticum). One hundred percent of the L. monocytogenes strains were inhibited by 0.25 microg of gemifloxacin per ml, whereas 0% of the strains were inhibited by 0.25 microg of ciprofloxacin per ml. Vancomycin at 2 microg/ml inhibited all strains. Doxycycline and gentamicin at 4 microg/ml inhibited 94 and 49% of the strains, respectively, while ampicillin at 0.5, 2, and 8 microg/ml inhibited 24, 61, and 66% of the strains, respectively. It is concluded that gemifloxacin shows good in vitro activity against L. monocytogenes and coryneform bacteria except C. jeikeium and C. urealyticum.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11451706      PMCID: PMC90663          DOI: 10.1128/AAC.45.8.2390-2392.2001

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  17 in total

1.  Increasing incidence of Corynebacterium group D2 strains resistant to norfloxacin and ciprofloxacin.

Authors:  F Soriano; R Fernández-Roblas; J Zapardiel; J L Rodríguez-Tudela; P Avilés; M Romero
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1989-12       Impact factor: 3.267

2.  In vitro susceptibility of Corynebacterium group D2 and Corynebacterium jeikeium to twelve antibiotics.

Authors:  A Philippon; F Bimet
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1990-12       Impact factor: 3.267

3.  Species identities and antimicrobial susceptibilities of corynebacteria isolated from various clinical sources.

Authors:  P Riegel; R Ruimy; R Christen; H Monteil
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1996-08       Impact factor: 3.267

4.  Most Corynebacterium xerosis strains identified in the routine clinical laboratory correspond to Corynebacterium amycolatum.

Authors:  G Funke; P A Lawson; K A Bernard; M D Collins
Journal:  J Clin Microbiol       Date:  1996-05       Impact factor: 5.948

5.  The in-vitro activity and tentative breakpoint of gemifloxacin, a new fluoroquinolone.

Authors:  R Wise; J M Andrews
Journal:  J Antimicrob Chemother       Date:  1999-11       Impact factor: 5.790

6.  In-vitro activity of levofloxacin, ofloxacin and D-ofloxacin against coryneform bacteria and Listeria monocytogenes.

Authors:  L Martínez-Martínez; A Pascual; A I Suárez; E J Perea
Journal:  J Antimicrob Chemother       Date:  1999-06       Impact factor: 5.790

Review 7.  Clinical microbiology of coryneform bacteria.

Authors:  G Funke; A von Graevenitz; J E Clarridge; K A Bernard
Journal:  Clin Microbiol Rev       Date:  1997-01       Impact factor: 26.132

8.  Antimicrobial susceptibility patterns of some recently established coryneform bacteria.

Authors:  G Funke; V Pünter; A von Graevenitz
Journal:  Antimicrob Agents Chemother       Date:  1996-12       Impact factor: 5.191

9.  Susceptibility of urinary isolates of Corynebacterium group D2 to fifteen antimicrobials and acetohydroxamic acid.

Authors:  F Soriano; C Ponte; M Santamaría; A Torres; R Fernández-Roblas
Journal:  J Antimicrob Chemother       Date:  1987-09       Impact factor: 5.790

10.  In vitro activities of ketolide HMR 3647, macrolides, and clindamycin against Coryneform bacteria.

Authors:  L Martínez-Martínez; A Pascual; A I Suárez; E J Perea
Journal:  Antimicrob Agents Chemother       Date:  1998-12       Impact factor: 5.191

View more
  5 in total

1.  Antipropionibacterial activity of BAL19403, a novel macrolide antibiotic.

Authors:  Stefanie Heller; Laurenz Kellenberger; Stuart Shapiro
Journal:  Antimicrob Agents Chemother       Date:  2007-03-26       Impact factor: 5.191

2.  Relationship between mutations in the gyrA gene and quinolone resistance in clinical isolates of Corynebacterium striatum and Corynebacterium amycolatum.

Authors:  Josep M Sierra; Luis Martinez-Martinez; Fernando Vázquez; Ernest Giralt; Jordi Vila
Journal:  Antimicrob Agents Chemother       Date:  2005-05       Impact factor: 5.191

3.  Activities of ABT-773 against Listeria monocytogenes and coryneform bacteria of clinical interest.

Authors:  María del Carmen Conejo; Luis Martínez-Martínez; Alvaro Pascual; Ana Isabel Suárez; Evelio J Perea
Journal:  Antimicrob Agents Chemother       Date:  2003-04       Impact factor: 5.191

Review 4.  Corynebacterium urealyticum: a comprehensive review of an understated organism.

Authors:  Nagla Salem; Lamyaa Salem; Sally Saber; Ghada Ismail; Martin H Bluth
Journal:  Infect Drug Resist       Date:  2015-05-21       Impact factor: 4.003

5.  Virulence and Antibiotic Resistance Genes in Listeria monocytogenes Strains Isolated From Ready-to-Eat Foods in Chile.

Authors:  Julio Parra-Flores; Ondrej Holý; Fernanda Bustamante; Sarah Lepuschitz; Ariane Pietzka; Alejandra Contreras-Fernández; Claudia Castillo; Catalina Ovalle; María Paula Alarcón-Lavín; Ariadnna Cruz-Córdova; Juan Xicohtencatl-Cortes; Jetsi Mancilla-Rojano; Miriam Troncoso; Guillermo Figueroa; Werner Ruppitsch
Journal:  Front Microbiol       Date:  2022-02-21       Impact factor: 5.640

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.